Justine Corli1, René-Marc Flipo1, Peggy Philippe1, Anne Bera-Louville1, Hélène Béhal1, Cécile Wibaux1, Julien Paccou2. 1. From the Department of Rheumatology, and Department of Biostatistics, Lille University Hospital, Lille, France.J. Corli, Resident, Department of Rheumatology, Lille University Hospital; R. Flipo, MD, PhD, Department of Rheumatology, Lille University Hospital; P. Philippe, MD, Department of Rheumatology, Lille University Hospital; A. Bera-Louville, MD, Department of Rheumatology, Lille University Hospital; H. Béhal, MSc, Department of Biostatistics, Lille University Hospital; C. Wibaux, MD, Department of Rheumatology, Lille University Hospital; J. Paccou, MD, PhD, Department of Rheumatology, Lille University Hospital. 2. From the Department of Rheumatology, and Department of Biostatistics, Lille University Hospital, Lille, France.J. Corli, Resident, Department of Rheumatology, Lille University Hospital; R. Flipo, MD, PhD, Department of Rheumatology, Lille University Hospital; P. Philippe, MD, Department of Rheumatology, Lille University Hospital; A. Bera-Louville, MD, Department of Rheumatology, Lille University Hospital; H. Béhal, MSc, Department of Biostatistics, Lille University Hospital; C. Wibaux, MD, Department of Rheumatology, Lille University Hospital; J. Paccou, MD, PhD, Department of Rheumatology, Lille University Hospital. julienpaccou@yahoo.fr.
Abstract
OBJECTIVE: The purpose of this study was to (1) evaluate baseline characteristics of nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) treated with tumor necrosis factor-α inhibitors (TNFi), (2) assess the response to first TNFi treatment, and (3) compare drug-survival duration and rates. METHODS: Inclusion criteria were patients with axSpA who initiated first TNFi treatment between April 2001 and July 2014 and were followed up for at least 3 months. Efficacy criteria were an improvement of at least 2 points (on a 0-10 scale) or a 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Baseline characteristics, responses at 12 months, and drug survival were compared between AS and nr-axSpA. RESULTS: A total of 361 patients were included in the study (AS, n = 263 and nr-axSpA, n = 98). Patients with AS were more often men (65.02% vs 45.92%, p = 0.001) and had longer symptom duration (11.71 ± 9.52 vs 7.34 ± 9.30 yrs, p < 0.001). Median levels of acute-phase reactants (C-reactive protein and erythrocyte sedimentation rate) were significantly higher in patients with AS (p < 0.001 for both). Median BASDAI scores at first TNFi initiation were not higher in patients with nr-axSpA than in patients with AS (59, 49-70 vs 60, 50-70, p = 0.73). BASDAI 20 and BASDAI 50 response rates at 12 months were not statistically different between patients with AS and patients with nr-axSpA (74.58% vs 64.58%, p = 0.19 and 61.02% vs 50.00%, p = 0.19, respectively). No statistically significant difference in terms of survival was observed between patients with AS and nr-axSpA (p = 1.00). CONCLUSION: Treatment response and drug survival were similar in patients with AS and nr-axSpA after first TNFi initiation.
OBJECTIVE: The purpose of this study was to (1) evaluate baseline characteristics of nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) treated with tumor necrosis factor-α inhibitors (TNFi), (2) assess the response to first TNFi treatment, and (3) compare drug-survival duration and rates. METHODS: Inclusion criteria were patients with axSpA who initiated first TNFi treatment between April 2001 and July 2014 and were followed up for at least 3 months. Efficacy criteria were an improvement of at least 2 points (on a 0-10 scale) or a 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Baseline characteristics, responses at 12 months, and drug survival were compared between AS and nr-axSpA. RESULTS: A total of 361 patients were included in the study (AS, n = 263 and nr-axSpA, n = 98). Patients with AS were more often men (65.02% vs 45.92%, p = 0.001) and had longer symptom duration (11.71 ± 9.52 vs 7.34 ± 9.30 yrs, p < 0.001). Median levels of acute-phase reactants (C-reactive protein and erythrocyte sedimentation rate) were significantly higher in patients with AS (p < 0.001 for both). Median BASDAI scores at first TNFi initiation were not higher in patients with nr-axSpA than in patients with AS (59, 49-70 vs 60, 50-70, p = 0.73). BASDAI 20 and BASDAI 50 response rates at 12 months were not statistically different between patients with AS and patients with nr-axSpA (74.58% vs 64.58%, p = 0.19 and 61.02% vs 50.00%, p = 0.19, respectively). No statistically significant difference in terms of survival was observed between patients with AS and nr-axSpA (p = 1.00). CONCLUSION: Treatment response and drug survival were similar in patients with AS and nr-axSpA after first TNFi initiation.
Authors: U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking Journal: Z Rheumatol Date: 2019-12 Impact factor: 1.372
Authors: Xabier Michelena; Sizheng Steven Zhao; Sayam Dubash; Linda E Dean; Gareth T Jones; Helena Marzo-Ortega Journal: Rheumatology (Oxford) Date: 2021-12-01 Impact factor: 7.580
Authors: Adrian Ciurea; Seraphina Kissling; Kristina Bürki; Xenofon Baraliakos; Manouk de Hooge; Monika Hebeisen; Eleftherios Papagiannoulis; Pascale Exer; René Bräm; Michael J Nissen; Burkhard Möller; Diego Kyburz; Michael Andor; Oliver Distler; Almut Scherer; Raphael Micheroli Journal: RMD Open Date: 2022-02